

BIOMARKERcenter

THE SINGLE, COMPREHENSIVE RESOURCE ON BIOMARKERS
AT ALL STAGES OF DRUG DEVELOPMENT



DISCOVER THE BIOMARKERS

- associated with a disease and the confidence-level for each biomarker
- affected by modifying target activity
- available for safety and toxicity use
- for your patient population stratification
- with the utility to move your compound from discovery to clinic

WHO CAN BENEFIT

- Discovery biologists
- Pre-clinical scientists
- Pharmacologists
- Toxicologists
- Clinical researchers
- Clinicians
- Translational researchers
- Bioinformaticians

THE NEW STANDARD IN BIOMARKER RESEARCH

BIOMARKERcenter is the only database that supports biomarker research across the entire profile of the disease.

It covers all key biomarker uses at every stage of drug R&D to provide a unique biomarker knowledge store including:

- proof of mechanism
- detecting risk of disease development
- diagnosis
- treatment/safety monitoring
- outcome measurement

By drawing on data from literature, patents, conferences, medical meetings and other sources, *BIOMARKERcenter* supports translational research by connecting experimental research and clinical studies for pivotal insights and decision making.

BIOMARKERcenter is the first biomarker database to provide standardized terminology, and the only one to classify biomarkers reliably into lifecycle phases and disciplines.


It is reliable in content, rich in analysis and backed up by rigorous editorial standards. It efficiently supports your knowledge to make go/no go decisions and to plan and execute clinical trials.

It is available in the following formats:

- a subscription option to *Prous Science Integrity*[®]
- an XML feed for your in-house informatics solutions
- an online stand alone database

BIOMARKERcenter monitors the lifecycle status of the biomarker use from discovery to approval—a pipeline approach that highlights confidence-level, while providing references for the basis of the categorization.

DISTRIBUTION AND FREQUENCY OF BIOMARKER USES ACROSS THE R&D PIPELINE GROUPED BY LIFECYCLE PHASE



DISCOVERY BIOLOGISTS

BIOMARKERcenter can help you to learn the biology of the disease you're working on, and to understand the current research situation regarding biomarkers in your therapy area. You can choose the biomarker that will give early indications on whether modifying a potential target has a positive outcome on the disease process.

PRECLINICAL SCIENTISTS

BIOMARKERcenter can help you to find the biomarkers that show the effects of your compound on the disease state. You can select suitable biomarkers for use in safety and efficacy studies to give early indication of toxicity and proof of concept.

CLINICAL TRIAL MANAGERS AND CLINICIANS

BIOMARKERcenter can help you to find the population that will respond best to the particular treatment. Knowing which biomarkers to use can improve the design and efficiency of your studies, and improve your probability of success.

TRANSLATIONAL RESEARCHERS

BIOMARKERcenter can help you to assign the right biomarker to the right project as early as possible enabling you to maximize the benefit of using biomarkers in a development project.

RELIABLE KNOWLEDGE, PLACED IN CONTEXT AND ASSESSABLE AT A GLANCE

The initial focus of *BIOMARKERcenter* was the major therapy areas including:

- oncology
- cardiovascular disease
- diabetes
- immunology
- respiratory diseases
- neurological disorders

Therapy areas are continually being expanded and now cover, pain, infectious disease, musculoskeletal and connective tissue disorders and endocrine disease.

For each therapy area, it includes not only biomarkers with established commercial presence but also high potential biomarkers as identified by industry and academia experts.

Uniquely, *BIOMARKERcenter* places this wealth of knowledge in context, enabling you to assess the relative importance of each biomarker by navigating seamlessly through the associated:

- drugs and biologics
- targets and pathways*
- patents
- genomics
- experimental pharmacology*
- clinical studies*
- companies and research institutions
- literature

*available only when integrated with *Prous Science Integrity*®

Each record in *BIOMARKERcenter* is enriched still further with links to supporting and refuting source documents.

Each manually curated record includes:

- the biomarker's name and synonyms
- its classification
- the biological entities/processes involved
- the associated drugs and mechanisms of action
- its roles or utilities
- measurement techniques
- FDA approved kits

SUPPORTING BIOMARKER ACCEPTANCE AND PHARMACEUTICAL INNOVATION

BIOMARKERcenter is compiled and curated by the experts at Thomson Reuters, a world authority on the pharmaceutical industry, with extensive participation by key opinion leaders and stakeholders in research and academia.

Dynamic, up-to-date, and continually enlarged, it puts at your disposal the most complete, reliable and high quality biomarker information available to the global pharmaceutical community.

By helping you to explore hypotheses and discover data from many different angles, *BIOMARKERcenter* can give you the biomarker knowledge you need to improve cost efficiency, predict and minimize risk, avoid late stage attrition and make better, more informed decisions.

Scientific Head Offices**Americas**

Philadelphia +1 800 336 4474
+1 215 386 0100
San Diego +1 858 273 8616

Europe, Middle East and Africa

Barcelona +34 93 459 2220
London +44 20 7433 4000

Asia Pacific

Singapore +65 6411 6888
Tokyo +81 3 5218 6500

For a complete office list visit:

scientific.thomsonreuters.com/contact

GET A QUOTATION

Contact us today to request a no obligation quotation or visit scientific.thomsonreuters.com

